Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is the comparision between the effects of vitamin D or placebo supplementation for 2 months in serum level of thioredoxin, TBP-2 and thioredoxin reductase activity in patients with type 2 diabetes
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| diabetes, vitamin D | Active Comparator | patients with type 2 diabetes who receive 4000 IU/day vitamin D |
|
| placebo, diabetes | Placebo Comparator | patients with type 2 diabetes who receive one tab placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| vitamin D | Dietary Supplement | one tab 4000 IU/day vitamin D |
| |
| Measure | Description | Time Frame |
|---|---|---|
| serum total cholesterol | change from baseline at 2 months | |
| serum HDL cholesterol | change from baseline at 2 months | |
| serum triglycerides level | change from baseline at 2 months | |
| fasting plasma glucose | change from baseline at 2 months | |
| serum LDL cholesterol | change from baseline at 2 months | |
| complete blood count (CBC) | change from baseline at 2 months | |
| HbA1c | change from baseline at 2 months | |
| serum insulin | change from baseline at 2 months | |
| serum calcidiol | change from baseline at 2 months | |
| thioredoxin | change from baseline at 2 months | |
| thioredoxin binding protein 2 (TBP-2) | change from baseline at 2 months | |
| erytrocyte thioredoxin reductase |
| Measure | Description | Time Frame |
|---|---|---|
| GENE EXPRESSION OF TBP-2 | change from baseline at 2 months |
Not provided
Inclusion Criteria:
literate, willingness to participation, diabetic patients 30- 60 years old, body mass index in the range 18.5- 35, avoidance of dietary supplements, vitamins and herbal products at least 3 months before and throughout the intervention -
Exclusion Criteria:
people who have used vitamin D supplements in last 3 months, having chronic renal disease , GI disease, Hepatobilliary diseases, hematological disorders, hypo- or hyperthyroidism, treatment with orlistat or sibutramine for weight loss, pregnancy and lactation, treatment with insulin or Thiazolidinediones, Smokers
-
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tehran University of Medical Sciences | Tehran | Tehran Province | Iran | |||
| Tehran University of Medical Sciences |
Not provided
Not provided
Not provided
Not provided
Not provided
| placebo |
| Dietary Supplement |
one tab per day placebo |
|
| change from baseline at 2 months |
| Tehran |
| Iran |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D014807 | Vitamin D |
| ID | Term |
|---|---|
| D012632 | Secosteroids |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
Not provided
Not provided